NEW YORK, October 20, 2017 /PRNewswire/ --
According to data provided by Grand View Research Inc., the global cancer immunotherapy market is expected to
reach USD 118.8 billion by 2025. The market is expected to benefit from introduction of newer drug
classes, such as target receptors for multiple myeloma and checkpoint inhibitors. Monoclonal antibodies are the most widely used
immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the
approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Majority of
cancer immunotherapy drugs have been used in treatment of non-small cell lung cancer, breast cancer, and prostate cancer. Regen
Biopharma, Inc. (OTC: RGBP), Advaxis, Inc. (NASDAQ: ADXS), OncoSec Medical Incorporated (NASDAQ: ONCS), Infinity Pharmaceuticals,
Inc. (NASDAQ: INFI), Curis, Inc. (NASDAQ: CRIS)
"Furthermore, increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of
new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new
immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their
ability to provide better cancer treatment," Grand View Research indicates.
Regen Biopharma, Inc. (OTCQB: RGBP) on October 16th announced breaking news that it,
"believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.
The Company recently reported that it identified key structural elements in small molecules that make them active and
specific towards the NR2F6 target. Now, further chemical testing has revealed dozens of compounds which activate NR2F6
which contain the key motif discovered.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint)
and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to
unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the
immune system in diseases where the immune system is over-activated, such as autoimmunity."
"Because our medicinal chemists were able to identify key structural elements in prior experiments, we can now add those
elements to new compounds and screen other compounds that have that structure," says Harry Lander, Ph.D., MBA, President and
Chief Scientific Officer of Regen. "We did this and discovered dozens of new compounds that profoundly activated NR2F6. We
are now selecting the best for further study."
"We are very excited at how well the medicinal chemistry program is working," says David Koos, Ph.D., Chairman & CEO
Regen BioPharma Inc. "We will file additional composition of matter patents around these structures shortly and we should be able
to focus on just one or two of the best ones moving forward."
Advaxis, Inc. (NASDAQ: ADXS) is a late-stage biotechnology company focused on the discovery, development and
commercialization of proprietary Lm-based antigen delivery products. On September 19, 2017, the
company announced two abstracts were selected for presentation at the 32nd annual Society for Immunotherapy of Cancer (SITC)
meeting. The conference is renowned for its scientific exchange, education and mission to improve patient outcomes through
advancement of science and the cancer immunotherapy field. "We're grateful to be sharing these meaningful findings with the rest
of the immunotherapy community," said Dr. Robert Petit, chief scientific officer at Advaxis. "Each
poster presentation allows members of our field to discuss new findings and approaches, with the goal of bringing improved
treatment options to patients.
OncoSec Medical Incorporated (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies
with an investigational technology, ImmunoPulse®, for the treatment of cancer. Recently, the company announced updated Phase 2
clinical and immune monitoring data from patients treated with its investigational therapy, ImmunoPulse® IL-12 as a monotherapy
versus the combination of ImmunoPulse IL-12 and the approved anti-PD-1 therapy pembrolizumab. These data were presented in an
oral presentation at the 2017 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research, and
continue to support the rationale for the Company's recently initiated global, open-label, Phase 2b registration directed trial,
PISCES/KEYNOTE-695.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is an innovative biopharmaceutical company dedicated to advancing novel
medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively
inhibits PI3K-gamma. Recently, the company announced that an abstract describing new data for IPI-549 has been selected as a
late-breaking presentation during an oral session at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking
place in National Harbor, MD, November 10 - 12. Additionally, a clinical trials in progress poster will also be presented on
the Phase 1/1b clinical study which is ongoing to explore the safety and activity of IPI-549 both as a monotherapy and in
combination with Opdivo® (nivolumab), a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors. IPI-549 is
believed to be the only PI3K-gamma inhibitor in clinical development.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on the development and commercialization of innovative and
effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being
investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with
Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to
oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule
antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the
IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors
and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in
other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in
this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information
posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality
and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not
offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with
financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique
financial newswire and media platform. For this release, FinancialBuzz.com expects to be compensated five
thousand dollars for financial news dissemination and pr services by a non-affiliate third party for regen biopharma, inc.
Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or
a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the
balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in
securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the
information on the editorial or Site or continue to post information about any companies the information contained herein is not
intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation.
The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members
and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site,
company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors
accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation
of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and
website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time.
None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any
particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication
is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment
strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree
to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no
representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change
without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com